Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
Journal of Hematology & Oncology volume 14, Article number: 101 (2021)
KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes by inhibiting NAMPT-dependent NAD+ production. NAMPT is the rate-limiting enzyme in the salvage metabolic pathway leading to NAD+ generation. Tumor cells which are deficient in de novo pathway enzyme NAPRT1 are addicted to NAMPT. In clinical trials, treatment with NAMPT inhibitors resulted in dose-limiting toxicities. In order to dissect the mechanism of toxicity, mice were treated with KPT-9274 and resulting toxicities were characterized histopathologically and biochemically. KPT-9274 treatment caused gender-dependent stomach and kidney injuries and anemia. Female mice treated with KPT-9274 had EPO deficiency and associated impaired erythropoiesis. KPT-9274 treatment suppressed SIRT3 expression and concomitantly upregulated acetyl-manganese superoxide dismutase (MnSOD) in IMCD3 cells, providing a mechanistic basis for observed kidney toxicity. Importantly, niacin supplementation mitigated KPT-9274-caused kidney injury and EPO deficiency without affecting its efficacy. Altogether, our study delineated the mechanism of KPT-9274-mediated toxicity and sheds light onto developing strategies to improve the tolerability of this important anti-AML inhibitor.
To the Editor,
The therapeutic potential of targeting NAMPT, an NAD+ biosynthetic enzyme, has been demonstrated in several cancers. Several NAMPT inhibitors have entered phase I trials to date (e.g. FK866, GMX1777, and KPT-9274) [1,2,3,4]. However dose-limiting toxicities such as thrombocytopenia and gastrointestinal (GI) toxicities have been observed. While the preclinical toxicity profile of KPT-9274 (the first orally bioavailable NAMPT inhibitor) [5, 6] recapitulates the expected class level GI and hematopoietic toxicities clinically , the preclinical retinal or cardiac toxicities, seen with other NAMPT inhibitors , were not observed. Though KPT-9274 treatment did not impair leukocyte viability in vitro, reduced red blood cell counts in patients given KPT-9274 clinically has been reported . Mitigating any potential toxicity and improving the tolerability are unmet needs for this class of inhibitors. Herein, we conducted in vivo studies to dissect the potential side effects and underlying mechanisms.
Tumor-free mice were treated with a therapeutically effective dose of KPT-9274 (150 mg/kg, p.o.) or the vehicle once daily. Mild cell death/loss of gastric epithelial cells (Fig. 1B) and tubular epithelial injury, as evident by cortical collapse and interstitial fibrosis in kidneys (Fig. 1C), were observed in the KPT-9274-treated group with no noticeable injuries in the small intestine and eyes. Lesions were much more severe in female mice (Fig. 1C) with robust renal cell death as evidence by TUNEL-positive regions (Fig. 1D). Interestingly, blood-urea-nitrogen (BUN) levels in KPT-9274-treated female NRGS mice were significantly higher than those of vehicle-treated counterparts, while in both genders of NSG mice, they are comparable between treatment groups (Fig. 1E). KPT-9274 treatment did not alter creatinine levels and BUN/creatinine ratios in both NSG and NRGS mice (Fig. 1E and Additional file 1: Figure S1). KPT-9274 treatment didn’t alter serum potassium and chloride levels in both genders, but reduced sodium levels in female mice (Additional file 1: Table 1).
Anemia and kidney injury have been linked to erythropoietin (EPO) production deficiency. Female KPT-9274-treated mice had consistently lower levels of EPO (Fig. 1F and Additional file 1: Figure S2), which were inversely correlated with increased severities of kidney injury (Fig. 1G). Concomitantly, the number of red blood cells and other CBC parameters (HCT, HBG, MCV, MCH and reticulocyte) were reduced in female mice, suggestive of anemia associated with KPT-9274 treatment (Fig. 1H and Additional file 1: Figure S3). KPT-9274 treatment resulted in lower percentage of late stage Ter119high erythroblasts and rise of ProE cells in bone marrow of female mice (Fig. 1I and Additional file 1: Figure S4). Within Ter119high population, the frequency of late basophilic and polychromatic erythroblasts (EryB) was increased and concomitantly orthochromatic erythroblasts (EryC) was markedly reduced, suggesting inhibition of erythroblast differentiation and production of mature erythroblast subsets.
Sirtuin-3 (SIRT3) is a NAD+-dependent lysine deacetylase that participates in mitochondrial respiration. SIRT3 is also implicated in renal function through the regulation of reactive oxygen species (ROS). In IMCD3 cells treated with KPT-9274, we observed a dose-dependent decrease in SIRT3 expression and a concomitant rise in acetyl-manganese superoxide dismutase (Fig. 1J) and ROS production (Fig. 1K). Additionally, KPT-9274 treatment caused PARP1/caspase-3/caspase-7 cleavage and enhanced the frequency of apoptotic cells which can be rescued by SIRT3 activator, Honokiol (Fig. 1L). These results suggest that KPT-9274-induced nephrotoxicity results from the reduced activity of SIRT3.
The activation of the NAPRT1-depended salvage pathway through the supplementation of niacin  as an alternative way for NAD+ production, has been shown to circumvent the toxicity seen with NAMPT inhibitors. Tumor-specific promoter hypermethylation and loss of NAPRT1 protein expression have also been observed in subtypes of lung, pancreatic, and ovarian cancers , making these tumors highly dependent on NAMPT for NAD+ production. We showed that co-administration of 30 mg/kg of niacin orally decreased the magnitude of renal lesions without affecting serum levels of creatinine and BUN in KPT-9274-treated NSG mice (Fig. 2A–C) and rescued the decreased EPO levels caused by KPT-9274 (Fig. 2D). KPT-9274 maintained its efficacy toward NAPRT1-negative AML cells with niacin supplement (Fig. 2E).
In conclusion, our study delineated the mechanism of KPT-9274-mediated toxicity and sheds light onto developing strategies to improve the tolerability of this important anti-AML inhibitor. Our data also reaffirm that stratifying patients by NAMPT and NAPRT1 levels may determine the patient population that will benefit the most from NAMPT inhibition.
Availability of data and materials
Acetyl-manganese superoxide dismutase
Reactive oxygen species
Acute myeloid leukemia
Holen K, Saltz LB, Hollywood E, Burk K, Hanauske A-R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Investig New Drugs. 2008;26(1):45–51.
von Heideman A, Berglund A, Larsson R, Nygren P. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother Pharmacol. 2010;65(6):1165–72.
Sampath D, Zabka TS, Misner DL, O’Brien T, Dragovich PS. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol Ther. 2015;151:16–31.
Naing A, Leong S, Pishvaian M, Razak A, Mahipal A, Berlin J, et al. A First in human phase 1 STUDY of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL. Ann Oncol. 2017;28.
Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, et al. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 2019;3(3):242–55.
Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH. Dual and specific inhibition of NAMPT and PAK4 By KPT-9274 decreases kidney cancer growth. Mol Cancer Ther. 2016;15(9):2119–29.
London C, Brown M, Warry E, Schuh E, Senapedis WT, Argueta C, et al. Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma. Cancer Res. 2017;77(13 Supplement):LB-308.
Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin Cancer Res. 2013;19(24):6912–23.
This work was supported by the NIH, NCI (R35 CA197734, R01 CA223165), the OSU Comprehensive Cancer Center using the Pelotonia Foundation funds.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mitchell, S., Zhang, P., Cannon, M. et al. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. J Hematol Oncol 14, 101 (2021). https://doi.org/10.1186/s13045-021-01107-0